XML 42 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration Agreements And Business Development Activities (Tables)
 6 Months Ended
Jul. 01, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Revenues Under Collaboration Agreement
Revenues under the collaboration agreement with Ipsen were as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
License revenues$51,168 $33,656 $75,782 $56,107 
Collaboration services revenues11,072 57,265 20,985 68,620 
Total$62,240 $90,921 $96,767 $124,727 
Revenues under the collaboration agreement with Takeda were as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
License revenues$2,700 $2,097 $5,065 $3,398 
Collaboration services revenues3,785 4,024 7,487 8,159 
Total$6,485 $6,121 $12,552 $11,557 
License revenues under the collaboration agreement with Genentech were as follows (in thousands):
 Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
Profits on U.S. commercialization$1,682 $2,160 $3,821 $3,954 
Royalty revenues on ex-U.S. sales$889 $782 $2,517 $1,733